Summary
The elderly form an important target group for the treatment of urinary urge incontinence with drugs such as terodiline (Mictrol, Terolin). In order to evaluate its steady-state pharmacokinetics and tolerability in geriatric patients terodiline 12.5 mg b.d. was given to 28 hospitalized patients with urinary incontinence (mean age 85 years) for six weeks. The patients were monitored during the study and for 6 weeks afterwards, blood samples being taken at regular intervals. In addition to these multi-diseased and polymedicated patients, a small, homogenous group of healthy volunteers (mean age 40 years) was studied as a reference group, being given terodiline 12.5 mg b.d. for 2 weeks.
Terodiline was generally well tolerated by the patients and no significant change in blood pressure or heart rate were found. One patient was withdrawn due to adverse effects. The mean terminal half-life of terodiline was 131 h and the clearance after oral administration (clearance/systemic availability) was 39 ml·min−1. The corresponding figures for the healthy volunteers were 57 h and 75 ml·min−1.
The average steady-state serum concentration was 518 µg·l−1 in the geriatric patients and 238 µg·l−1 in the healthy volunteers. Steady-state was reached within 3 weeks in 20 of the 28 patients and within 5 weeks in 7 patients.
In the geriatric patients the steady-state serum concentration of the main metabolite p-hydroxyterodiline, during the last three weeks on terodiline was 45 µg·l−1, 57 µg·l−1, and 45 µg·l−1, respectively, and a similar value was found in the healthy volunteers, 47 µg·l−1. The serum concentration of p-hydroxy-m-methoxyterodiline was <15 µg·l−1 both in the geriatric patients and in the healthy volunteers.
Thus, terodiline 25 mg/day given to fragile elderly patients was well tolerated. It produced serum concentrations similar to those found after the standard dose of 37.5–50 mg given to younger, healthier patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersson K-E (1984) Clinical pharmacology of terodiline. Scand J Urol Nephrol [Suppl] 87: 13–20
Beisland HO, Fossberg E (1985) The effects of terodiline and meladrazine on severe motor urge incontinence in geriatric patients. J Am Geriatr Soc 33: 29–32
Bradley WE, Sundin T (1982) The physiology and pharmacology of urinary tract dysfunction. Clin Neuropharmacol 5: 131–158
Castenfors H, Hedenstierna G, Glenne P-O (1975) Pilot study of the effect of terodiline chloride (Bicor) in obstructive pulmonary disease. Eur J Clin Pharmacol 8: 197–200
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41
Ekman G, Andersson K-E, Rud T, Ulmsten U (1980) A double-blind cross-over study of the effects of terodiline in women with unstable bladder. Acta Pharmacol Toxicol 46 [Suppl I]: 39–43
Elmér M (1984) Terodiline in children with diurnal enuresis. Scand J Urol Nephrol [Suppl] 87: 59–61
Fischer-Rasmussen W and The Multicentre Study Group (1984) Evaluation of long-term safety and clinical benefit of terodiline in women with urgency/urge incontinence. A multicentre study. Scand J Urol Nephrol [Suppl] 87: 35–47
Gerstenberg TC, Klarskov P, Ramirez D, Hald T (1986) Terodiline in the treatment of women with urgency and motor urge incontinence. A clinical and urodynamic double-blind cross-over study. Br J Urol 58: 129–133
Hallén B, Magnusson A, Bogentoft S, Ekelund P (1988a) Single-dose and multiple-dose pharmacokinetics of terodiline in geriatric patients. Eur J Clin Pharmacol 34: 291–297
Hallén B, Guilbaud O, Strömberg S, Lindeke B (1988b) Single-dose pharmacokinetics of terodiline in man, including a stable isotope technique for improvement of statistical evaluations. Biopharm Drug Dispos 9: 229–250
Husted S, Andersson K-E, Sommer L, Östergaard JR (1980) Anticholinergic and calcium antagonistic effects of terodiline in rabbit urinary bladder. Acta Pharmacol Toxicol 46 [Suppl I]: 20–30
Karlén B, Andersson K-E, Ekman G, Strömberg S, Ulmsten U (1982) Pharmacokinetics of terodiline in human volunteers. Eur J Clin Pharmacol 23: 267–270
Klarskov P, Gerstenberg TC, Hald T (1986) Bladder training and terodiline in females with idiopathic urge incontinence and stable detrusor function. Scand J Urol Nephrol 20: 41–46
Macfarlane JR, Tolley DA (1984) The effect of terodiline on patients with detrusor instability. Scand J Urol Nephrol [Suppl] 87: 51–54
Norén B, Strömberg S, Ericsson Ö, Lindeke B (1988) Biotransformation of Terodiline. IV. Identification of unconjugated and conjugated metabolites in dog and human urine. Acta Pharm Suec 25: 281–292
Petersen T, Jakobsen J (1987) A calcium blocking and anticholinergic agent (terodiline) in the treatment of detrusor hyperreflexia: a placebo-controlled, cross-over trial. J Neurol Neurosurg Psychiatry 50: 1131–1136
Peters D and The Multicentre Study Group (1984) Terodiline in the treatment of urinary frequency and motor urge incontinence. A controlled multicentre trial. Scand J Urol Nephrol [Suppl] 87: 21–33
Rud T, Andersson K-E, Boye N, Ulmsten U (1980) Terodiline inhibition of human bladder contraction. Effects in vitro and in women with unstable bladder contraction. Acta Pharmacol Toxicol 46 [Suppl I]: 31–38
Sjögren C, Andersson K-E, Husted S, Mattiasson A, Møller-Madsen B (1982) Atropine resistance of transmurally stimulated isolated human bladder muscle. J Urol 128: 1368–1371
Sole GM, Arkell DG (1984) A symptomatic and cystometric comparison of terodiline with emepronium in the treatment of women with frequency, urgency and incontinence. Scand J Urol Nephrol [Suppl] 87: 55–57
Ulmsten U, Ekman G, Andersson K-E (1985) The effect of terodiline treatment in women with motor urge incontinence. Am J Obstet Gynecol 153: 619–622
Vessman J, Strömberg S (1969) Determination of terodiline (Bicor) in serum by gas chromatography and electron capture detection of benzophenone formed by chromic acid oxidation. Acta Pharm Suec 6: 505–518
Wibell L (1968) Terodiline in angina pectoris — a controlled study of a new drug. Acta Soc Med Upsal 73: 75–80
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hallén, B., Bogentoft, S., Sandquist, S. et al. Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence. Eur J Clin Pharmacol 36, 487–493 (1989). https://doi.org/10.1007/BF00558074
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558074